Schonfeld Strategic Advisors LLC Mirati Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

$13.8 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $1.24 Million - $1.84 Million	-29,539 Reduced 96.22%	1,161 $68,000
Q3 2023 Nov 14, 2023	SELL	$27.8 - $45.35 $2.75 Million - $4.49 Million	-98,936 Reduced 76.32%	30,700 $1.34 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $3.86 Million - $5.29 Million	106,837 Added 468.6%	129,636 $4.68 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $533,447 - $792,141	14,599 Added 178.04%	22,799 $847,000
Q4 2022 Feb 14, 2023	SELL	$41.27 - $98.62 $628,418 - $1.5 Million	-15,227 Reduced 65.0%	8,200 $371,000
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $510,153 - $743,365	-8,574 Reduced 26.79%	23,427 $1.64 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $1.25 Million - $2.84 Million	32,001 New	32,001 $2.15 Million
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $1.24 Million - $2.47 Million	-16,350 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $313,787 - $452,319	-2,377 Reduced 12.69%	16,350 $2.4 Million
Q3 2021 Nov 16, 2021	SELL	$132.13 - $177.45 $1.51 Million - $2.02 Million	-11,395 Reduced 37.83%	18,727 $3.31 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $4.34 Million - $5.41 Million	30,122 New	30,122 $4.87 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $268,892 - $374,964	-1,692 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $15,232 - $22,585	-94 Reduced 5.26%	1,692 $373,000
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $429,595 - $634,455	-3,793 Reduced 67.99%	1,786 $0
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $797,582 - $1.33 Million	-11,076 Reduced 66.5%	5,579 $637,000
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $801,213 - $1.33 Million	-11,482 Reduced 40.81%	16,655 $1.28 Million
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $6.85 Million - $12.5 Million	-96,863 Reduced 77.49%	28,137 $3.63 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $7.43 Million - $10.5 Million	-95,400 Reduced 43.28%	125,000 $9.74 Million
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $3.52 Million - $6.2 Million	59,200 Added 36.72%	220,400 $22.7 Million
Q1 2019 May 15, 2019	BUY	$43.65 - $78.95 $3.07 Million - $5.55 Million	70,300 Added 77.34%	161,200 $11.8 Million
Q4 2018 Feb 14, 2019	BUY	$32.0 - $47.43 $1.16 Million - $1.73 Million	36,400 Added 66.79%	90,900 $3.86 Million
Q3 2018 Nov 14, 2018	SELL	$47.1 - $62.7 $1.63 Million - $2.17 Million	-34,600 Reduced 38.83%	54,500 $2.57 Million
Q2 2018 Aug 14, 2018	BUY	$26.05 - $52.4 $2.32 Million - $4.67 Million	89,100 New	89,100 $4.39 Million
Q1 2018 May 15, 2018	SELL	$17.2 - $34.95 $552,343 - $1.12 Million	-32,113 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$12.65 - $19.0 $406,229 - $610,147	32,113	32,113 $586,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Account